Introduction
Recently anti-cancer research refocused on the power of Mother Nature to efficiently fight cancer. Natural sources provide a rich repository of save compounds and examination of these natural products has provided evidence for their anticancer potential. One major advantage of naturally occurring drugs relative to synthetic chemicals is their lack of toxicity towards healthy tissues. Additionally, natural products have specific bioactivity and bioavailability. Thus, the trend to treat illnesses with naturally discovered lead compounds has established a basis for the development of novel cancer therapies.
Chalcones belong to the polyphenol family, represent natural antioxidants, are commonly found in fruits and vegetables, and serve as precursors for flavonoid synthesis. Because they are abundant in edible plants, they seem to be promising representatives for dietary cancer prevention strategies [1] . Additionally, their simple and efficient synthesis makes them also attractive for cancer therapy.
Several studies have shown that the anti-proliferative effects on cancer cells are associated with the presence of hydroxyl group/s in chalcone molecules; therefore, hydroxyl-derivates of chalcone have more potent anti-proliferation properties compared to the other chalcone derivatives [2] [3] [4] . Additionally, the position of the hydroxyl group within the chalcone molecule seems to play an important role in the activity of the molecule. Chemically, 4 0 -hydroxychalcone is an alpha, beta-unsaturated ketone with the core structure of chalcone (1,3-diphenyl-2-propenone) and one hydroxyl-substituent on the 4 0 position of the A ring ( Fig. 1 ). Because nuclear factor (NF)-kB is irreversibly connected with inflammatory processes involved in wide range of severe diseases including cancer and because it has been shown to induce resistance to various chemotherapeutic agents, targeting this pathway by natural compounds is an attractive strategy to attenuate and overcome cancer development [5] [6] [7] [8] [9] [10] . The NF-kB family includes 5 family members: RelA (p65), RelB, c-Rel, p50/ p105 (NF-kB1) and p52/p100 (NF-kB2), which can form homo-and hetero-dimeric protein complexes. By binding of the dimers to corresponding DNA sequences in promoter or enhancer regions, the expression of pro-inflammatory genes is increased while the expression of other genes is repressed [11] . The most common NFkB dimer is the p50/p65 heterodimer, which is involved in canonical NF-kB pathway activation. In the presence of divergent extrinsic signals (cytokines, carcinogens, UV light, physical and chemical stress or proliferating agents), inhibitor of NF-kB (IkB) is phosphorylated by IkB kinase (IKK), ubiquitinated and marked for the proteasomal degradation [12] . Subsequently, the NF-kB dimer is no longer sequestered in the cytoplasm and rapidly translocates to the nucleus where it can transactivate more than 550 genes.
To date, a large spectrum of natural, plant-derived, polyphenols was identified and investigated for its NF-kB inhibition potential. Additionally, the ability to synthesize original natural compounds A B S T R A C T Chalcones are aromatic ketones, known to exhibit anti-microbial, anti-inflammatory and anti-cancer activities. The aim of this study was to investigate the anti-inflammatory and anti-cancer activity of 4 0 -hydroxychalcone. Here, we report that 4 0 -hydroxychalcone inhibits TNFa-induced NF-kB pathway activation in a dose-dependent manner. To investigate the underlying molecular mechanisms we demonstrate that 4 0 -hydroxychalcone inhibits proteasome activity in a dose-dependent manner but has no effect on IKK activity. Results show that 4 0 -hydroxychalcone inhibits TNFa-dependent degradation of IkBa and subsequently prevents p50/p65 nuclear translocation leading to 4 0 -hydroxychalcone-inhibited expression of NF-kB target genes. Most importantly, inhibition of NF-kB activation by 4 0 -hydroxychalcone is not leukemia cell-type specific and has no significant effect on non-transformed cell viability, thus highlighting the compound's potential in both prevention and treatment.
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or to modify their structures to improve their bioactivity opens a new horizon of potential novel molecules with anticancer potential.
In this study, we provided a detailed biological analysis of the involvement of 4 0 -hydroxychalcone in NF-kB regulation in different leukemic cell lines and tried to elucidate the mechanistic background underlying the inhibitory potential of 4 0 -hydroxychalcone. We showed that 4 0 -hydroxychalcone significantly repressed the tumor necrosis factor alpha (TNFa)-induced NFkB pathway and NF-kB target genes. Interestingly, we discovered a strong negative effect of 4 0 -hydroxychalcone on proteasomal activities, explaining its involvement in the NF-kB cascade. Moreover, we provided evidence of the selective cytotoxic effect of 4 0 -hydroxychalcone on cancer cells by a comparative study with a non-cancer cells. Thus, we identified mechanisms, which make 4 0 -hydroxychalcone an interesting, safe and promising inhibitor of TNFa-induced NF-kB activation pathway.
Materials and methods

Compounds and purification
TNFa was purchased from Sigma-Aldrich (Bornem, Belgium) and dissolved to a concentration of 10 mg/mL in 1Â PBS supplemented with 0.5% (w/v) BSA, according to the manufacturer's instructions. 4 0 -Hydroxychalcone was a gift from laboratory of Dr. Deniz Tasdemir (Department of Pharmaceutical and Biological Chemistry, School of Pharmacy of University of London, England). The compound, with a molecular weight of 224.27 g/mol, was received as a powder and solubilized in 100% DMSO (Sigma-Aldrich, Bornem, Belgium) to obtain a stock concentration of 100 mM. This stock solution was then further diluted in DMSO to obtain working aliquots. Both stock and working solutions were frozen at À20 8C. Control cells were treated with equivalent amounts of DMSO.
Cell culture
K562 (human chronic myelogenous leukemia), U937 (histiocytic lymphoma) and Jurkat (T-cell leukemia) cells (DSMZ) were cultured in RPMI medium (Lonza, Verviers, Belgium) supplemented with 10% (v/v) fetal calf serum (Lonza, Verviers, Belgium) and 1% (v/v) antibiotic-antimycotic (Bio-Whittaker, Verviers, Belgium) at 37 8C and 5% CO 2 . The cells were harvested every 3 days. After thawing, the cells were kept in normal culture conditions for 10 days before experiments.
At T 0 , the cells were treated with 4 0 -hydroxychalcone at various concentrations. At T 0 + 2 h the cells were activated by addition of TNFa (20 ng/mL). Controls and test samples were then incubated for the appropriate time at 37 8C.
Healthy blood samples were kindly donated as buffy coats by the Red Cross (Luxembourg, Luxembourg). Diluted (1/3) blood in RPMI 1640 was layered onto Ficoll and centrifuged (400 Â g, 20 min) to isolate mononuclear cells. The isolated peripheral blood mononuclear cells (PBMCs) were kept in culture at 37 8C and 5% CO 2 for 24 h before they were subjected to treatments.
Electrophoretic mobility shift assay (EMSA)
Both K562 and Jurkat cells that were cultured in growth medium (RPMI, 0.1% FCS) at a concentration of 3 Â 10 5 cells/mL and were pre-treated in the presence and absence of 4 0 -hydroxychalcone (30 mM) for 4, 8 or 16 h before being activated by TNFa (20 ng/mL) for 30 min, or for indicated time period. Cells were then harvested and washed twice in 1Â PBS. Supernatants were discarded and cell pellets were stored overnight at À80 8C. Nuclear protein extractions were performed as described previously, and nuclear extracts were stored at À80 8C [13] . The oligonucleotide NF-kBc (consensus NF-kB site) (Eurogentec, Liè ge, Belgium) (5 0 -AGTTGAGGGGACTTTCCCAGGC-3 0 ) and its complementary sequence were used as probes. After hybridization, the probes were radiolabeled using [g-32 P]-ATP (MP-Biomedicals, Illkirch, France) and the EMSA assay was performed according to conditions established before [13] . First, 10 mg of nuclear proteins were incubated with the radiolabeled probe in binding buffer for 20 min on ice. Then the DNA-protein complexes were separated on a 5% polyacrylamide gel followed by visualization by autoradiography.
Transient transfection and luciferase reporter gene assay
K562 cells were transiently transfected as described previously [13] . inhibitor of kB kinase beta (IKKb), tumor growth factor activated kinase 1 (TAK1) and TAK1-binding protein 1 (TAB1)) were added to the electroporation mixture. Cells were resuspended in normal culture medium (RPMI, 10% FCS) after electroporation and cultured at 37 8C and 5% CO 2 for 24 h. After the required incubation time, cells were harvested and resuspended in fresh growth medium (RPMI, 0.1% FCS) to a final concentration of 1 Â 10 6 cells/mL and pre-treated for 2 h with 4 0 -hydroxychalcone at varying concentrations. Activation with 20 ng/mL of TNFa for 6 h followed the pre-treatment. For co-transfection experiments only TNF indicated control was activated by TNFa. After the 8 h incubation, 75 mL of Dual-Glo TM Luciferase Reagent (Promega, Leiden, Netherlands) was added to 75 mL of the cellular suspension for 10 min incubation at 22 8C before luciferase activity measurement. Subsequently, 75 mL of Dual-Glo
TM
Stop&Glo
1 Reagent (Promega, Leiden, Netherlands) was added for 10 min at 22 8C to the cell suspension to measure Renilla activity. An Orion microplate luminometer (Berthold) was used to measure luciferase and Renilla activity. The results are expressed as a ratio of arbitrary units of firefly luciferase activity to Renilla luciferase activity. 
Cell viability assessment
Cell survival percentages were evaluated using Promega's CellTiter-Glo 1 Luminescent Cell Viability Assay kit (Promega, Leiden, Netherlands) according to the manufacturer's instructions. Briefly, the assay determines the number of viable cells based on the quantification of ATP as an indicator of metabolic activity. ATP is measured using the luciferase catalysis of luciferin to oxyluciferin and light in the presence of Mg 2+ , ATP and oxygen. The lyophilized enzyme/substrate mixture was reconstituted with the provided buffer. Then, an equal volume of the reaction buffer was added to medium containing K562, U937, Jurkat or PBMC cells (untreated or treated with 4 0 -hydroxychalcone at the indicated concentrations and times). The mixture was shaken on a rocking platform for 2 min and then incubated for 10 min in the dark at RT. The luminescence signal, which is proportional to the amount of ATP present, was quantified using a Berthold Orion microplate luminometer and converted into the number of viable cells according to the manufacturer's instructions. Data were normalized to the control and reported as percentage of viable cells.
Extraction of cellular proteins
After the indicated incubation times with 4 0 -hydroxychalcone and TNFa, the K562 and Jurkat cells were lysed, and the nuclear and cytoplasmic extracts were prepared according to [13] . Briefly, 10 7 cells per sample were lysed in a hypertonic detergent medium containing protease inhibitor cocktail (Complete 1 , Roche, Luxembourg). The extraction was performed on ice to avoid protein degradation. The suspension was put on a vertical agitation shaker for 15 min at + 4 8C and was then centrifuged at 15,000 Â g for 15 min at +4 8C for suspension clearing. Afterwards, supernatants were removed and aliquots were stored at À80 8C until use.
Western Blot analysis
Proteins of nuclear and cytoplasmic extracts were separated by size using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE, 10%), transferred onto nitrocellulose membranes and blocked with 5% non-fat milk in phosphate buffered saline (PBS)-Tween for 1 h. Lamin B for cytoplasmic extracts and atubulin for nuclear extracts, were used as loading controls. Blots were then incubated with primary antibodies: anti-pIkBa (1/300, Cell Signaling 9246, Bioké , Leiden, Netherlands), anti-IkBa (1/500 Santa Cruz SC-371, Tebu-Bio, Boechout, Belgium), anti-p50 (1/ 5000, Santa Cruz SC-7178X), anti-p65 (1/5000, Santa Cruz SC-8008), anti-a-tubulin (1/5000, Calbiochem CP06, VWR, Leuven, Belgium) or anti-lamin B (1/1000, Santa Cruz SC-6216). All antibodies were diluted in a PBS-Tween solution containing 5% bovine serum albumin (BSA) or 5% milk according to the providers' protocols. After incubation with primary antibodies, membranes were washed 3 Â 10 min with PBS-Tween followed by an incubation of 1 h at RT with the corresponding secondary (HRPconjugated) antibodies. After washing 3 Â 10 min with PBSTween, specific immunoreactive proteins were visualized by autoradiography using the ECL Plus Western Blotting Detection System Kit 1 (GE Healthcare, Roosendaal, Netherlands).
Human CXCL8/IL-8 immunoassay
IL-8 concentrations in culture supernatants of activated K562 cells were measured by sandwich ELISA (R&D Systems, Abingdon, United Kingdom). According to the manufacturer's guide, 50 mL of cell supernatants were added with 100 mL of Assay Diluent to anti-IL-8 pre-coated wells followed by 2 h incubation at RT. After washing, a polyclonal peroxidase-conjugated anti-IL-8 antibody was added for another 60 min at RT. Colorimetric visualization and protein dosage were developed by addition of the H 2 O 2 + TMB (tetramethylbenzidine) containing substrate. After a 30 min reaction at room temperature (RT) in the dark, the enzymatic reaction was stopped by addition of H 2 SO 4 and optical densities were measured at a wavelength of 450 nm.
IKK kinase activity assay
The K-LISA TM IKKb-Inhibitor Screening Kit (Calbiochem, San Diego, CA) was used for rapid in vitro screening of IKKb inhibitors. The ELISA-based activity assay utilizes a 50-amino acid GST-IkBa fusion polypeptide substrate with Ser32 and Ser36 IKKb phosphorylation sites. The GST-IkBa substrate and IKKb were incubated in the presence of IKKb inhibitors in a GlutathioneCoated 96-Well plate. The incubation of GST-IkBa substrate and IKKb allowed for substrate phosphorylation and capture in a single step. The phosphorylated GST-IkBa substrate was detected using an Anti-Phospho IkBa (Ser32/Ser36) antibody, followed addition of the HRP-Conjugate and colorimetric development with TMB Substrate. ELISA Stop Solution was used to stop the colorimetric development and the absorbance was read at 450 nm, preferably with a reference wavelength of 540-600 nm, using a SpectraCount UV-spectrometer (Packard, Groningen, Netherlands). The absorbance is directly related to the level of IKKb activity. IKK-2 Inhibitor IV ([5-(p-fluorophenyl)-2-ureido]thiophene-3-carboxamide) (Calbiochem, San Diego, CA) was used as a positive control.
Proteasome inhibition activity
The Proteasome-Glo TM Chymotrypsin-like Cell-Based Assay shaking for 2 min and an additional incubation period of 10 min at room temperature, the luminescence was measured on a luminometer (Berthold). A viability assay using CellTiter-Glo 1 Luminescent Cell Viability Assay Kit (Promega, Leiden, Netherlands) was performed in parallel to normalize the proteasome activity to the number of viable cells.
Statistical analysis
Data are expressed as mean AE SD. Significance was determined by the Student's t-tests. P-values below 0.05 were considered as statistically significant.
Results
4
0 -Hydroxychalcone inhibits TNFa-induced NF-kB pathway activation in a dose-dependent manner
The NF-kB pathway is engaged in many inflammatory processes. Its involvement in various malignancies suggests that its activation is linked to cancer development and progression. Therefore, we were interested to see how 4
0 -hydroxychalcone interferes with the classical model of pro-inflammatory signaling through the TNFa-induced NF-kB transcriptional pathway.
To examine the inhibitory potential of 4 0 -hydroxychalcone on NF-kB activity we used a reporter gene assay. K562 cells transfected with a luciferase reporter gene were pre-treated with different concentrations of 4 0 -hydroxychalcone for 2 h and then treated with TNFa (20 ng/mL) for an additional 6 h. Results showed that TNFa led to strong activation of the NF-kB pathway in control cells and that 4 0 -hydroxychalcone inhibited the TNFadriven NF-kB pathway activation in a dose-dependent manner with an IC 50 of 30 mM (Fig. 2A) . The IC 50 value was calculated using XY scatter dependency chart applying the best fitting trend formula model. The average of three IC 50 values from three independent experiments was applied.
Additionally, because TNFa triggers the NF-kB pathway by sequentially activating TNFR1, TRADD, TRAF2 and IKK, thus leading to IkBa phosphorylation, we wanted to elucidate where exactly 4 0 -hydroxychalcone inhibits this cascade. Recently, the importance of TAK1 in the TNF-induced NF-kB activation pathway has been reported [14] . These studies indicated that TNFa stimulation leads to formation of the TAK1, TRAF2, IKKa and IKKb complex and results in IKK activation. Thus, we transiently co-transfected K562 cells with TNFR1-, TRADD-, TRAF2-, NIK-, TAK1-, TAB1-, and IKKbexpressing plasmids along with a NF-kB-regulated luciferase reporter construct. The luciferase assay revealed that cells cotransfected with each of these plasmids expressed the NF-kBregulated reporter gene and that 4 0 -hydroxychalcone significantly suppressed the NF-kB reporter activity in cells co-transfected with TNFR1, TRAF2 or TAK1, but had no inhibitory effect on the activity in cells overexpressing TRADD, IKKb, NIK or TAB1 (Fig. 2B) . These results indicate involvement of 4 0 -hydroxychalcone on the receptor and the primary signaling complex.
0 -Hydroxychalcone has no direct effect on IKK activity
Degradation of IkBa depends either on IKK activity or on proteasome activity. Chronologically, IKK activity occurs prior to proteasomal activity. To further confirm our previous results showing the inability of 4 0 -hydroxychalcone to effect directly IKK activity, we monitored IKKb activity by ELISA in the presence of 4 0 -hydroxychalcone. The ELISA used an IkBa substrate and IKKb HisTag 1 protein.
We tested a wide spectrum of concentrations (from 10 mM to 1000 mM) of 4 0 -hydroxychalcone and showed that 4 0 -hydroxychalcone was not able to significantly inhibit IKKb activity at any tested concentrations (Fig. 3) .
We concluded that the inhibitory potential of 4 0 -hydroxychalcone on NF-kB is independent of direct IKK activity.
0 -Hydroxychalcone inhibits proteasome activity in a dosedependent manner
We were interested if proteasomal activity was involved in the mechanism by which the chalcone derivative inhibits the NF-kB pathway. We evaluated the protease inhibition activity of 4 0 -hydroxychalcone on three different proteolytic activities (chymotrypsin-, trypsin-and caspase-like) of the 26S proteasome at a concentration range between 0.1 mM and 25 mM 4 0 -hydroxychalcone in K562 and U937 leukemia cells. 4 0 -hydroxychalcone was able to inhibit each of the 3 major proteolytic activities in a dosedependent manner in both cell lines (Fig. 4A and B) .
Thus, 4 0 -hydroxychalcone significantly repressed all three proteasomal activities. We showed a positive correlation between dose of 4 0 -hydroxychalcone and its inhibitory potential.
0 -Hydroxychalcone inhibits TNFa-dependent degradation of IkBa and prevents p50/p65 nuclear translocation Degradation of NF-kB natural inhibitor IkBa represents the initial step in NF-kB activation. Thus, we assessed IkBa stability in the cytoplasm and translocation of the NF-kB subunits p65 and p50, from the cytoplasm to the nucleus by Western blot analysis. Control cells activated by TNFa showed the classical model of NFkB pathway activation:degradation of IkBa appearing at 10 min after stimulation and the re-appearance of IkBa at 60 min after stimulation. Degradation occurs by a negative feedback loop because p50/p65 binding to DNA induces IkBa gene expression. We also observed nuclear translocation of p50 and p65 15 min Each value is a mean AE SD of three determinations. Asterisks indicate a significant difference compared to the negative control as analyzed by t-test (*p < 0.05; **p < 0.01; ***p < 0.001). after TNFa stimulation. However, 4 0 -hydroxychalcone was able to considerably postpone and attenuate IkBa degradation and prevented the cytoplasmic to nuclear translocation of both the p50 and p65 subunits of the NF-kB heterodimer (Fig. 5) .
To confirm previous results showing that 4 0 -hydroxychalcone can block TNFa-dependent p50/p65 nuclear translocation, we performed an EMSA to determine if 4 0 -hydroxychalcone can prevent NF-kB binding to DNA. K562 cells were exposed to 4 0 -hydroxychalcone for different time intervals and were then treated for 30 min TNFa. Results presented in Fig. 6A shows that 30 mM 4 0 -hydroxychalcone suppressed TNFa induced NF-kB activation for up to 16 h (Fig. 6A) .
As the active NF-kB dimer may consist of various combinations of Rel/NF-kB proteins, we wanted to show that the band visualized by EMSA represented the p50/p65 NF-kB heterodimer. We incubated the nuclear extract from TNFa-stimulated cells with anti-p50 or anti-p65 antibodies. The results shown in Fig. 6B and D indicate that in K562 and Jurkat cells, respectively, TNFa-activated complex consisted of p50 and p65 subunits because the major bands were shifted to a higher molecular mass (Fig. 6B and D) .
Inhibition of NF-kB activation by 4
0 -hydroxychalcone is not celltype specific Because NF-kB induction can be mediated in different cell types by specific signal transduction pathways, we examined whether 4 0 -hydroxychalcone is able to suppress the activity of NF-kB in different cell types. We treated Jurkat cells with 4 0 -hydroxychalcone at a concentration corresponding to the IC 50 of NF-kB inhibition (30 mM) and then further cultured the cells in the presence or absence of TNFa. EMSA analysis, shown in Fig. 6C , confirmed that 4 0 -hydroxychalcone is able to inhibit TNFainduced NF-kB activation in cells other than the K562 leukemic cell line, specifically in the Jurkat T-cell leukemia cell line. This indicates that the effect of 4 0 -hydroxychalcone on TNFa-induced NF-kB activation is not cell type specific. Additionally, 4 0 -hydroxychalcone alone did not activate NF-kB signaling pathway (Fig. 6C ).
4 0 -Hydroxychalcone inhibits the expression of NF-kB target genes
TNFa is known to induce the expression of many genes involved in cancer proliferation and metastasis. Additionally, many of these genes have an NF-kB binding site in their promoters. As described above, 4 0 -hydroxychalcone is able to down-regulate NFkB activity. We were interested if this negative regulation affected NF-kB target gene expression. To further investigate the effects of 4 0 -hydroxychalcone on downstream NF-kB signaling, we focused on two proteins, which are known to be under the NF-kB control: IL-8 and ICAM-1. We applied two different strategies to study possible changes in gene expression. First, we used an ELISA assay to measure changes in IL-8 production 24 h after treatment with 4 0 -hydroxychalcone. IL-8 is a pro-inflammatory CXC chemokine and its expression is primarily regulated by NF-kB. Two hours after treatment with 4 0 -hydroxychalcone, K562 cells were incubated in the presence or absence of TNFa. Control cells produced markedly low amounts of IL-8 (165 pg/ml) while TNFa stimulation led to a rapid increase of IL-8 levels (1305 pg/ml). We observed that cells pretreated with 4
0 -hydroxychalcone at a concentration of 60 mM produced significantly lower levels of IL-8 (702 pg/ml). Observed decrease in IL-8 release relative to cells stimulated with TNFa but not treated with 4 0 -hydroxychalcone is up to 40% (Fig. 7A ). Secondly, we examined whether 4 0 -hydroxychalcone affects ICAM-1 gene transcription. ICAM-1 is involved in cell invasion [15] . K562 cells were transiently transfected with ICAM-1 plasmid along with the Renilla reporter plasmid and after 24 h incubation the cells were pre-treated with 30 mM of 4 0 -hydroxychalcone(concentration corresponding to IC 50 for NF-kB inhibition) for 2 h. The cells were then treated with TNFa for an additional 6 h. The induction of ICAM-1 by TNF occurred within 6 h and was rapidly downregulated by 4 0 -hydroxychalcone (Fig. 7B ).
4
0 -Hydroxychalcone affects cancer cell viability but has no significant effect on non-transformed cell viability A current limitation in cancer treatment is the toxicity of active compounds to non-cancerous tissues. Thus, we were interested to To assess whether 4 0 -hydroxychalcone could inhibit cell growth, K562, U937, Jurkat cells and PBMCs were treated with 4 0 -hydroxychalcone at concentrations ranging from 5 mM to 60 mM. We first studied viability after 8 h of treatment because this time frame corresponds to the length of the treatment for several of our previous experiments. Cell viability after 8 h was determined using the CellTiter-Glo 1 Reagent, which quantitatively measures ATP levels to signify the presence of metabolically active cells. The inhibitory potential of 4 0 -hydroxychalcone was calculated relative to cells without any treatment. Fig. 8A shows that after 8 h 4 0 -hydroxychalcone significantly inhibited cell viability in all three cancer cell lines in a dose-dependent manner. However, the cell viability of PBMCs was not affected by 4 0 -hydroxychalcone even at the highest concentrations.
We also wanted to know how cell viability might change after prolonged 4 0 -hydroxychalcone treatment. After 24 h of treatment with 4 0 -hydroxychalcone, cell viability was dramatically affected in all three cancer cell lines (Fig. 8B) . A significant decrease in cell viability was observed at 10 mM 
Discussion
The goal of the present study was to determine if 4 0 -hydroxychalcone is able to inhibit the TNFa-induced NF-kB pathway and if so, how this inhibition is mediated. Several hydroxyl-derivatives of chalcones that do not contain other substituent groups have been shown to possess potent antiinflammatory properties [3, 4] . Naringenin chalcone, which is abundant in tomato skin and has 3 hydroxyl-groups, inhibited the production of TNFa in lipopolysaccharide (LPS)-stimulated macrophages [16] . Isoliquiritigenin (also with three hydroxyl-groups) down-regulated NF-kB activation by suppression of IKK, resulting in inhibition of the phosphorylation and subsequent degradation of IkBa [17] [18] [19] . Butein (with four hydroxyl-groups) has been shown to attenuate IkBa phosphorylation by direct inactivation of IKK through cysteine residue 179 [20] . Based on structure-activity relationship studies, natural chalcone-based NF-kB inhibitors contain preferentially hydroxyl or/and methoxy functional groups [21] . Yadav et al. summarized and compared the dose necessary for NF-kB inhibitory activity within a group of different chalcone derivatives focusing on the functional group/s they possess in their molecules. Interestingly, 2 0 -hydroxychalcone, structurally closely resembling our chalcone derivative in the present study, was able to inhibit NF-kB activity already at a three times lower dose compared to the basic chalcone or chalcone derivatives with more hydroxyl groups in their molecules, such as isoliquiritigenin and butein [22] . Based on these findings 4 0 -hydroxychalcone was a tempting candidate as an anti-inflammatory agent because it bears only one hydroxyl-group.
Here, we provided evidence showing the inhibitory potential of 4 0 -hydroxychalcone on the TNFa-induced NF-kB pathway in leukemic cell lines and elucidated the mechanism underlying this activity for the first time.
Specifically, we found that 4 0 -hydroxychalcone suppressed NFkB activation induced by TNFa in a dose-dependent manner. As aberrant NF-kB activity is typically linked to high TNFa concentrations in patients with myelodysplastic syndromes and because this high level of TNFa is believed to be responsible for leukemic properties, we used this model to study potential effects of 4 0 -hydroxychalcone on NF-kB [23] . Additionally, we were also interested where 4 0 -hydroxychalcone is involved in the NF-kB cascade. We demonstrated that 4 0 - hydroxychalcone has no direct effect on IKK but nevertheless may attenuate its activity indirectly through inhibition of particular members of the primary signaling complex. IKK activation has been linked to various kinases and signaling molecules [24, 25] . We found that 4 0 -hydroxychalcone blocked TNFR1-, TRAF2-and TAK1-mediated NF-kB activation. The importance of TRAF2, which is recruited to TNFR1 through TRADD-interaction and subsequently leads to activation of NF-kB, has been previously reported [26] . Similarly, TNFa activation of the NF-kB pathway is associated with inducible binding of TAK1 to TRAF2 and thus to both IKKa and IKKb [14] . TRAF2 and cellular inhibitors of apoptosis (cIAPs) are believed to cooperate by recruiting ubiquitin chains to receptor interacting protein (RIP). While TRAF2 seems to play a structural role, allowing recruitment of cIAPs to the vicinity of RIP, cIAPs can directly ubiquitinate RIP [27, 28] . This ubiquitination leads to attachment and activation of TAK1 kinase complex, which consist of TAK1 kinase and its associated proteins TAB1, TAB2 and TAB3, which in turn phosphorylates and activates IKK complex [29] [30] [31] [32] . The ability of 4 0 -hydroxychalcone to inhibit NF-kB activity induced in cells overexpressing TAK1 supports recent studies showing TAK1 as a critical component required for IkB kinase-mediated activation of the NF-kB pathway [33] . Contrariwise, when we induced the NF-kB pathway at the step of overexpressed TRADD, IKK or TAB1, we observed an induction instead of inhibition of NFkB-driven reporter gene activity. As we showed, 4 0 -OH induces the basal level of NF-kB activity (Fig. 2B, vector) . We hypothesized, that we can expect/observe the similar effect on the NF-kB activity driven by overexpression of proteins, which are not directly downregulated by 4 0 -OH. Apparently, the effect of 4 0 -OH on downregulation of NF-kB pathway is mediated by abrogation of other step/s of NF-kB canonical cascade. In the case of an up-regulation of the NF-kB activity driven by TRADD overexpression, the future analysis has to be done. In several cases, up-regulation of TRADD was linked to activation of apoptotic cell death [34, 35] . As we showed, that 4 0 -OH had a strong impact on cancer cell viability, upregulation of TRADD upon 4 0 -OH treatment could be connected to activation of cell death mechanism. Nevertheless, these findings need to be further elaborated.
NF-kB pathway can be activated in different manners according to a presence of specific dimer of NF-kB family. We used cells overexpressing NIK to get an insight into the second major NF-kB activation -the alternative pathway. The alternative pathway is involved during B and T cell organ development and is activated by the receptor controlled NIK kinase that promotes the processing of p52 precursor (p100) and translocation of the hetero-dimers p52-RelB to the nucleus [36] . Nevertheless, we did not observe any significant difference in NIK-transfected cells treated with 4 0 -OH in comparison to untreated cells. These results indicate that 4 0 -OH is not involved and cannot abrogate the alternative pathway.
The next step in the NF-kB activation cascade is through 26S proteasome function. Once the IKK complex is activated, it phosphorylates IkB proteins, which leads to their degradation by the 26S proteasome [24] . We hypothesize that even if 4 0 -hydroxychalcone does not directly affect IKK, it might prevent the proteasomal degradation of IkBa. Interestingly, by focusing on three main proteolytic sides, we showed that 4 0 -hydroxychalcone significantly down-regulated all three proteolytic activities in a dose-dependent manner in both K562 and U937 cell lines. To the best of our knowledge, our study is the first to indicate that 4 0 -hydroxychalcone inhibits NF-kB activation by suppression of proteasomal activities in leukemic cells.
Our proposed model of involvement of 4 0 -hydroxychalcone in the canonical cascade NF-kB is displayed in Fig. 9 .
Furthermore, we confirmed that 4 0 -hydroxychalcone reduced induction of NF-kB transcriptional activity by blocking TNFainduced p50/p65 heterodimer translocation to the nucleus and thus reduced and prevented NF-kB binding to target DNA.
Excessive production of TNFa by the tumor itself and by the tumor microenvironment is well documented. Many cancer cells constitutively secrete TNFa, which appears to contribute directly to oncogene activation, DNA damage and tumor growth [37] . TNFa can act as an endogenous tumor promoter and induce other inflammatory mediators such as IL-1, IL-6, IL-8 and TNFa itself [38] . Interestingly, IL-8 has been characterized as a significant regulatory factor within the tumor microenvironment and elevated concentrations of IL-8 were found in patients serum with different cancer malignancies such as breast [39, 40] , ovarian [41, 42] , prostate [43, 44] , lung [45] , pancreatic [46] and melanoma cancer [47] . Moreover, IL-8 has been linked to angiogenesis, tumorigenicity and tumor metastasis in several xenograft and orthotopic in vivo models [48] [49] [50] . Here, we provided evidence, that 4 0 -hydroxychalcone is able to inhibit the TNFa-induced IL-8 production in chronic myelogenous leukemia cells. The higher concentration of 4 0 -OH needed to reduce IL-8 production could be explained by activity of other transcription factors known to be involved in positive or negative regulation of IL-8 expression. The IL-8 promoter contains, among others, binding sites for the transcription factors AP-1, C-EBP/NF-IL6 and NF-kB [51] . Moreover, new findings indicate that besides other cytokines, oncogenic Ras up-regulates also the expression of IL-8 [52] and EGFR signaling positively regulates its synthesis and secretion in tumor cells [53] . Thus, the higher concentration of 4 0 -OH necessary for IL-8 inhibition could be explained due to the activity of other transcription factors, which boosted IL-8 expression.
Because TNFa is known to be one of the major inducers of divergent adhesion molecules in human endothelial cells and because the expression of TNF requires the activation of NF-kB, we examined the effect of 4 0 -hydroxychalcone on the TNF-mediated induction of intracellular adhesion molecule ICAM-1. We found that the expression of ICAM-1 was abrogated by 4 0 -hydroxychalcone. We also analyzed the effect of 4 0 -hydroxychalcone on cell viability. Loa et al. recently reported that 4 0 -hydroxychalcone had a cytotoxic effect on HepG2 cells [2] . Chemotherapeutic agents and radiation therapy unfortunately can activate NF-kB and can promote a cytotoxic effect on healthy tissues as well as cancer cells, causing side effects such as nephrotoxicity, hepatotoxicity, ototoxicity or neurotoxicity [54] . One strategy to overcome these adverse effects is to identify novel drugs lacking these side effects and develop the utility of these compounds in combinatory treatment with commercially available chemotherapy agents. Via comparative analysis, we determined the cytotoxic effect of 4 0 -hydroxychalcone on different cancer cell lines (K562, Jurkat, U937) and on healthy peripheral blood mononuclear cells (PBMCs). We showed that 4 0 -hydroxychalcone has selective cytotoxicity to the leukemic cells, which makes it an attractive candidate for cancer prevention and treatment.
In conclusion, we determined that 4 0 -hydroxychalcone is a potent inhibitor of TNFa-induced NF-kB activation and described the mechanism by which 4 0 -hydroxychalcone executes this inhibition. Moreover, we identified the 26S proteasome as a major molecular target of 4 0 -hydroxychalcone. The absence of toxicity on healthy cells makes 4 0 -hydroxychalcone an inviting candidate as a potential anti-cancer drug, whether used alone or in combinatory treatment with other chemotherapeutics.
